Larimar Therapeutics reported results for the second quarter of 2026, posting a net loss of $32.8M and a common diluted net loss per share of $0.3, compared with a net loss of $26.2M and diluted net loss per share of $0.41 in the year‑ago quarter.

Financial Highlights

• Net loss was $32.8M for 2Q 2026, versus a net loss of $26.2M in 2Q 2025 (loss widened by $6.6M YoY).
• Common diluted net loss per share was $0.30 for 2Q 2026, versus $0.41 for 2Q 2025 (improved EPS loss YoY).
• Six‑month results: Net loss was $62.4M for 1H 2026, versus a net loss of $55.5M for 1H 2025 (loss widened by $6.9M YoY).

Business Highlights

• Regulatory progress: Received FDA Breakthrough Therapy designation and continued alignment with the agency on using skin FXN as a surrogate endpoint for an accelerated BLA.
• Clinical milestones: Completed Phases 1–2; ongoing open‑label study with 43 patients dosed and over 10,000 doses administered; Phase 3 sites planned globally.
• Safety and efficacy: Longer‑term tolerability observed, sustained increases in skin FXN and directional clinical benefit versus natural history (mFARS benefit of +2.6 at one year).
• Commercial readiness: Rolling BLA initiated in June 2026 and commercial preparations scaled for a potential mid‑2027 launch.
• R&D and operations: Increased R&D and G&A spending to support the BLA, manufacturing scale‑up, inspection readiness and Phase 3 initiation.

Original SEC Filing: Larimar Therapeutics, Inc. [ LRMR ] - 10-Q - Aug. 04, 2026